Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Compass Therapeutics (CMPX) Long-Term Debt Issuances (2018 - 2019)

Compass Therapeutics recorded quarterly Long-Term Debt Issuances of $20985.0 in Q4 2019, up 67.88% quarter-over-quarter from $12500.0 in Q4 2018, and up 67.88% year-over-year from $12500.0 in Q4 2018.

Compass Therapeutics' Long-Term Debt Issuances history runs 2 years deep, the most recent figure standing at $20985.0 for Q4 2019.

  • In Q4 2019, Long-Term Debt Issuances rose 67.88% year-over-year to $20985.0; the TTM figure through Dec 2019 stood at $48585.0 (changed N/A YoY), while the FY2020 annual figure was $30985.0, down 17.59% from the prior year.
  • Long-Term Debt Issuances came in at $20985.0 for Q4 2019 at Compass Therapeutics, up from $12500.0 in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $20985.0 in Q4 2019 to a low of $12500.0 in Q4 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 2.73 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Compass Therapeutics 418.47 Mn 223.78 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2019 20,985.00
Dec 31, 2019 20,985.00
Dec 31, 2018 12,500.00
Dec 31, 2018 12,500.00
Jun 30, 2018 15,100.00
Jun 30, 2018 15,100.00